REXULTI (brexpiprazole): Approved as Adjunctive Therapy to Treat Adults with MDD and Schizophrenia – Drug Insights and Market Forecasts to 2032 – Focus on 7 Major Markets

Posted on by

DUBLIN, July 20, 2023 /PRNewswire/ — The “REXULTI Drug Insight and Market Forecast – 2032” drug pipelines has been added to ResearchAndMarkets.com’s offering. “This “REXULTI Drug Insight and Market Forecast – 2032” report provides comprehensive insights about REXULTI for schizophrenia in…